World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
165
Citations
102108
World Ranking
633
National Ranking
362

Overview

Guillermo Garcia-Manero is affiliated with The University of Texas MD Anderson Cancer Center in the United States. Their research primarily focuses on the field of Medicine, with extensive work spanning several specialized subfields including Hematology, Genetics, Molecular Biology, Public Health, Environmental and Occupational Health, and Oncology.

The scientist's research contributions cover a range of main topics related to blood cancers and hematologic conditions. These topics include Acute Myeloid Leukemia Research, Chronic Myeloid Leukemia Treatments, Myeloproliferative Neoplasms: Diagnosis and Treatment, Acute Lymphoblastic Leukemia Research, Chronic Lymphocytic Leukemia Research, Histone Deacetylase Inhibitors Research, and Hematopoietic Stem Cell Transplantation.

Among recent notable publications authored or co-authored by Guillermo Garcia-Manero are:

  • Acute myeloid leukemia: current progress and future directions, 2021, Blood Cancer Journal
  • Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes, 2020, New England Journal of Medicine
  • Eprenetapopt (APR-246) and Azacitidine in TP53-Mutant Myelodysplastic Syndromes, 2021, Journal of Clinical Oncology
  • Clonal evolution of acute myeloid leukemia revealed by high-throughput single-cell genomics, 2020, Nature Communications
  • Venetoclax Combined With FLAG-IDA Induction and Consolidation in Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia, 2021, Journal of Clinical Oncology

Garcia-Manero has frequently published in leading hematology and oncology journals. The most common publication venues include:

  • Blood
  • American Journal of Hematology
  • Journal of Clinical Oncology
  • Leukemia
  • Cancer

The scientist collaborates extensively with other researchers in the field. Frequent co-authors include Hagop M. Kantarjian, Tapan M. Kadia, Farhad Ravandi, Courtney D. DiNardo, and Elias Jabbour, each contributing to a significant number of joint publications.

Garcia-Manero's body of work addresses critical aspects of hematologic malignancies and related therapies, combining clinical investigation with molecular and genetic approaches to better understand disease mechanisms, diagnosis, and treatment options.

Best Publications

  • Guidelines for the use and interpretation of assays for monitoring autophagy

    Daniel J. Klionsky;Fabio C. Abdalla;Hagai Abeliovich;Robert T. Abraham

  • Revised International Prognostic Scoring System for Myelodysplastic Syndromes

    Peter L. Greenberg;Heinz Tuechler;Julie Schanz;Guillermo Sanz

  • Clinical effect of point mutations in myelodysplastic syndromes.

    Rafael Bejar;Kristen Stevenson;Omar Abdel-Wahab;Naomi Galili

  • Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in hematopoietic malignancies.

    Jean Pierre J. Issa;Guillermo Garcia-Manero;Francis J. Giles;Rajan Mannari

  • Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia

    Hagop Kantarjian;Yasuhiro Oki;Guillermo Garcia-Manero;Xuelin Huang

  • Genetic Alterations Activating Kinase and Cytokine Receptor Signaling in High-Risk Acute Lymphoblastic Leukemia

    Kathryn G. Roberts;Ryan D. Morin;Jinghui Zhang;Martin Hirst

  • Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies

    Omar Abdel-Wahab;Ann Mullally;Cyrus Hedvat;Guillermo Garcia-Manero

  • Treatment of Philadelphia chromosome–positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate

    Deborah A. Thomas;Stefan Faderl;Jorge Cortes;Susan O'Brien

  • Chemoimmunotherapy With Fludarabine, Cyclophosphamide, and Rituximab for Relapsed and Refractory Chronic Lymphocytic Leukemia

    William Wierda;Susan O'Brien;Sijin Wen;Stefan Faderl

  • Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia

    Deborah A. Thomas;Stefan Faderl;Susan O'Brien;Carlos Bueso-Ramos

  • Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents

    Hui Yang;Carlos Bueso-Ramos;Courtney DiNardo;Marcos R Estecio

  • CCAT2, a novel noncoding RNA mapping to 8q24, underlies metastatic progression and chromosomal instability in colon cancer

    Hui Ling;Riccardo Spizzo;Yaser Atlasi;Milena Nicoloso

  • TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients.

    Rafael Bejar;Allegra Lord;Kristen Stevenson;Michal Bar-Natan

  • New Comprehensive Cytogenetic Scoring System for Primary Myelodysplastic Syndromes (MDS) and Oligoblastic Acute Myeloid Leukemia After MDS Derived From an International Database Merge

    Julie Schanz;Heinz Tüchler;Francesc Solé;Mar Mallo

  • Phase 1/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemia.

    Guillermo Garcia-Manero;Hagop M. Kantarjian;Blanca Sanchez-Gonzalez;Hui Yang

  • Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System.

    Hagop Kantarjian;Susan O'Brien;Farhad Ravandi;Jorge Cortes

  • High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome–positive chronic phase chronic myeloid leukemia

    Hagop Kantarjian;Moshe Talpaz;Susan O'Brien;Guillermo Garcia-Manero

  • Maintenance therapy with low-dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome: a dose and schedule finding study.

    Marcos J.G. de Lima;Sergio Giralt;Peter F. Thall;Leandro De Padua Silva

  • Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes

    Guillermo Garcia-Manero;Hui Yang;Carlos Bueso-Ramos;Alessandra Ferrajoli

  • Validation of a Prognostic Model and the Impact of Mutations in Patients With Lower-Risk Myelodysplastic Syndromes

    Rafael Bejar;Kristen E. Stevenson;Bennett A. Caughey;Omar Abdel-Wahab

Frequent Co-Authors

Hagop M. Kantarjian
Hagop M. Kantarjian The University of Texas MD Anderson Cancer Center
Jorge E. Cortes
Jorge E. Cortes Augusta University
Farhad Ravandi
Farhad Ravandi The University of Texas MD Anderson Cancer Center
Elias Jabbour
Elias Jabbour The University of Texas MD Anderson Cancer Center
Gautam Borthakur
Gautam Borthakur The University of Texas MD Anderson Cancer Center
Naval Daver
Naval Daver The University of Texas MD Anderson Cancer Center
Sherry Pierce
Sherry Pierce The University of Texas MD Anderson Cancer Center
Susan O'Brien
Susan O'Brien University of California, Irvine
Marina Konopleva
Marina Konopleva The University of Texas MD Anderson Cancer Center
Stefan Faderl
Stefan Faderl The University of Texas MD Anderson Cancer Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you’re exploring careers in medicine but seeking alternative routes, there are several related online degrees and career pathways worth considering. Many students opt for nursing as a flexible and high-demand field. Some adn programs (Associate Degree in Nursing) are accessible entry points, making it easier to get started in healthcare.

Not all nursing schools require stringent entrance exams. In fact, you can find do all nursing schools require the teas information to identify programs that don’t mandate the TEAS or HESI, making the process smoother for applicants.

Alternatively, those interested in healthcare but not direct patient care might explore administrative or technical roles. Earning a degree from one of the best online medical billing and coding schools can help you start a career in medical records and health information technology.

Leadership-minded students might consider a healthcare administration degree to pursue management positions within hospitals, clinics, or community health organizations. These diverse pathways offer meaningful opportunities in the evolving healthcare sector.

Best Scientists Citing Guillermo Garcia-Manero

Trending Scientists